Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20547717 | 0.81 | L3MBTL1 (0.63) | L3MBTL1CYP3A4KMT2ALMNAMEN1 | |
| SCHEMBL26277118 | 0.78 | L3MBTL1 (0.54) | L3MBTL1CYP3A4KMT2ALMNAMEN1 | |
| SCHEMBL20936330 | 0.78 | L3MBTL1 (0.53) | L3MBTL1CYP3A4KMT2ALMNAMEN1 | |
| SCHEMBL25716301 | 0.76 | L3MBTL1 (0.55) | L3MBTL1CYP3A4KMT2ALMNAMEN1 | |
| SCHEMBL20936236 | 0.73 | HTT (0.52) | L3MBTL1CYP3A4KMT2ALMNAMEN1 | |
| SCHEMBL25416954 | 0.69 | L3MBTL1 (0.48) | L3MBTL1CYP3A4KMT2ALMNAMEN1 | |
| SCHEMBL25415355 | 0.68 | PDE4B (0.46) | L3MBTL1CYP3A4KMT2ALMNAMEN1 | |
| SCHEMBL20547944 | 0.67 | HTT (0.66) | L3MBTL1CYP3A4KMT2ALMNAMEN1 | |
| SCHEMBL22018952 | 0.67 | MAPT (0.60) | L3MBTL1LMNAHTTALDH1A1ALOX15 | |
| SCHEMBL22664569 | 0.65 | CYP3A4 (0.42) | L3MBTL1CYP3A4KMT2ALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813268-B2 | Mitofusin activators and uses thereof | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2023081835-A1 | EXPANDING T-CELL USING MITOFUSIN ACTIVATORS AND USES IN CANCER THERAPIES | EMORY UNIVERSITY (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2019079243-A1 | MITOFUSIN ACTIVATORS AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813268-B2 | Mitofusin activators and uses thereof | MFN2, TFB2M, PCK2 | L3MBTL1 1742/4885CYP3A4 4205/4885KMT2A 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.